Teplizumab: a new glimmer of hope for type 1 diabetic patients
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20231135Keywords:
Teplizumab, Monoclonal antibody, Immune cellsAbstract
Teplizumab is the first monoclonal antibody used to delay the onset of stage 3 type 1 diabetes mellitus (DM). It is a highly selective, a CD3-directed monoclonal antibody, given parenterally that was approved in November 2022, for delaying the onset of Stage 3 type 1 diabetes in adults and paediatric patients aged 8 years and older with stage 2 type 1 Diabetes. It binds to the immune cells that destroy the insulin producing pancreatic beta cells and inactivates them thereby leading to decreased rate of reduction in insulin production and subsequently delay in the onset of stage 3 type 1 diabetes.
References
Primavera M, Giannini C, Chiarelli F. Prediction and Prevention of Type 1 Diabetes. Front. Endocrinol. 11:248.
Powers AC. Type 1 diabetes mellitus: much progress, many opportunities. J Clin Invest. 2021;131(8):e142242.
Molina CE, "Oram RA.Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol. 2023;11(2):76-7.
Masharani UB, BeckerJ. Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther. 2010;10(3):459-65.
Skelley JW, Elmore LK, Kyle JA. Teplizumab for treatment of type 1 diabetes mellitus. Ann Pharmacother. 2012;46(10):1405-12
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013;56(2):391-400.
Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, et al. Immune therapy and β-cell death in type 1 diabetes. Diabetes. 2013;62(5):1676-80.
Perdigoto AL, Hurlburt PP, Clark P, Long SA, Linsley PS, Harris KM, et al. Immune Tolerance Network. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. 2019;62(4):655-64.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-13.
Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, et al . Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13:583.
Nourelden AZ, Elshanbary AA, El-Sherif L, Benmelouka AY, Rohim HI, Helmy SK, et al. Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis. EndocrMetab Immune Disord Drug Targets. 2021;21(10):1895-904.
